nct_id: NCT04771130
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2021-02-25'
study_start_date: '2021-05-24'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Azacitidine'
  - drug_name: 'Drug: Posaconazole'
  - drug_name: 'Drug: BGB-11417'
long_title: A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2
  Inhibitor BGB-11417 in Patients With Myeloid Malignancies
last_updated: '2025-11-12'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: BeOne Medicines
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 260
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Key Inclusion Criteria:'
- '1. Confirmed diagnosis of one of the following by 2016 World Health Organization
  criteria:'
- '* AML, nonacute promyelocytic leukemia'
- '* MDS'
- '* MDS/MPN'
- 2. Eastern Cooperative Oncology Group performance status of 0 to 2.
- '3. Adequate organ function defined as:'
- "* Creatinine clearance \u2265 50 milliliters/minute (mL/min) (or between 30 and\
  \ 49 mL/min in unfit AML cohort)"
- '* Adequate liver function'
- 4. Life expectancy of \> 12 weeks.
- 5. Ability to comply with the requirements of the study.
- 'Exclude - Key Exclusion Criteria:'
- Exclude - 1. A diagnosis of acute promyelocytic leukemia.
- "Exclude - 2. History of prior malignancy, with the exception of either a history\
  \ of MDS or MDS/MPN that has transformed to AML, or other prior malignancy that\
  \ was treated with a full curative intent and no evidence of recurrence within the\
  \ past 2 years (eg, localized skin cancer, superficial bladder cancer, carcinoma\
  \ in situ of the cervix or breast, or localized Gleason score \u2264 6 prostate\
  \ cancer)"
- Exclude - 3. Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia
  vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and
  AML with BCR-ABL1 translocation.
- Exclude - 4. Prior therapy with a B-cell lymphoma-2 inhibitor
- Exclude - 5. Known central nervous system involvement by leukemia.
- 'Exclude - Note: Other protocol defined Inclusion/Exclusion criteria may apply.'
short_title: A Study of BGB-11417 in Participants With Myeloid Malignancies
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: BeiGene
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The study will determine the safety, tolerability, recommended Phase 2 dose
  (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with
  azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic
  syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Parts 1 and 2: AML Cohorts'
      arm_internal_id: 0
      arm_description: Participants with AML will receive BGB-11417 and azacitidine
        on a 28-day cycle.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BGB-11417'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Azacitidine'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Parts 1 and 2: MDS Cohorts'
      arm_internal_id: 1
      arm_description: Participants with MDS will receive BGB-11417 and azacitidine
        on a 28-day cycle.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Azacitidine'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: BGB-11417'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Part 3: AML and MDS Cohorts'
      arm_internal_id: 2
      arm_description: Participants with AML and MDS will receive BGB-11417 and azacitidine
        on a 28-day cycle. A subset of the participants will receive a modified second
        cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BGB-11417'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Azacitidine'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Posaconazole'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Part 3: AML and MDS Cohort'
      arm_internal_id: 3
      arm_description: Participants with MDS and R/R AML (China only) will receive
        BGB-11417 on a 28-day cycle.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: BGB-11417'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - and:
        - or:
          - clinical:
              oncotree_primary_diagnosis: Myeloid Atypical
          - clinical:
              oncotree_primary_diagnosis: Myeloid Neoplasm
        - clinical:
            age_numerical: '>=18'
            disease_status:
            - Localized
      - and:
        - genomic:
            hugo_symbol: PML
            variant_category: '!Structural Variation'
        - genomic:
            hugo_symbol: BCR
            variant_category: '!Structural Variation'
